A Review of Nonantibiotic Agents to Prevent Urinary Tract Infections in Older Women

  • Christian M. Gill
    Henry Ford Hospital, Department of Pharmacy, Detroit, MI
    Search for articles by this author
  • Maria-Stephanie A. Hughes
    University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, RI

    Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, RI
    Search for articles by this author
  • Kerry L. LaPlante
    Address correspondence to Kerry L. LaPlante, PharmD, FCCP, FIDSA, Professor, University of Rhode Island, College of Pharmacy, 7 Greenhouse Rd, Suite 295A, Kingston, RI 02881.
    University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, RI

    Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, RI

    Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI
    Search for articles by this author



      This article provides a comprehensive literature review on nonantibiotic agents used for the prevention of urinary tract infections (UTIs) in women ≥45 years of age.


      A structured review was performed by conducting a literature search to identify relevant studies pertaining to the use of nonantibiotic agents to prevent UTIs in women who were perimenopausal through postmenopausal. Recommendations were made for or against the use of each nonantibiotic agent, unless data were unavailable. Levels of evidence were assigned to each recommendation made.

      Setting and participants

      Studies on the prevention of UTIs with women subjects ≥45 years of age in the community, inpatient, and long-term care settings were considered for inclusion.


      The efficacy and safety of using ascorbic acid, cranberry products, d-mannose, estrogens, lactobacilli, and methenamine hippurate for prevention of UTIs was assessed.


      There is evidence to support use of estrogens (A-I) in postmenopausal women, and cranberry capsules (C-I) in women ≥45 years of age for the prevention of UTIs. There was a lack of evidence to make recommendations for or against the use of ascorbic acid, cranberry juice, cranberry capsules with high proanthocyanidin (PAC) content, d-mannose, lactobacillus, and methenamine hippurate in this population.


      Current studies support that estrogens and cranberry capsules may have a role in preventing UTIs in women ≥45 years of age. Further research is needed to elucidate the role of these nonantibiotic agents and how they may be used to decrease antibiotic use.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dwyer L.L.
        • Harris-Kojetin L.D.
        • Valverde R.H.
        • et al.
        Infections in long-term care populations in the United States.
        J Am Geriatr Soc. 2013; 61: 342-349
        • Hu K.K.
        • Boyko E.J.
        • Scholes D.
        • et al.
        Risk factors for urinary tract infections in postmenopausal women.
        Arch Intern Med. 2004; 164: 989-993
        • Dason S.
        • Dason J.T.
        • Kapoor A.
        Guidelines for the diagnosis and management of recurrent urinary tract infection in women.
        Can Urol Assoc J. 2011; 5: 316-322
        • Raz R.
        • Gennesin Y.
        • Wasser J.
        • et al.
        Recurrent urinary tract infections in postmenopausal women.
        Clin Infect Dis. 2000; 30: 152-156
        • Stamm W.E.
        • Raz R.
        Factors contributing to susceptibility of postmenopausal women to recurrent urinary tract infections.
        Clin Infect Dis. 1999; 28: 723-725
        • Ryan S.
        • Gillespie E.
        • Stuart R.L.
        Urinary tract infection surveillance in residential aged care.
        Am J Infect Control. 2018; 46: 67-72
        • Rotjanapan P.
        • Dosa D.
        • Thomas K.S.
        Potentially inappropriate treatment of urinary tract infections in two Rhode Island nursing homes.
        Arch Intern Med. 2011; 171: 438-443
        • Mitchell S.L.
        • Shaffer M.L.
        • Loeb M.B.
        • et al.
        Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia.
        JAMA Intern Med. 2014; 174: 1660-1667
        • Albert X.
        • Huertas I.
        • Pereiro II,
        • et al.
        Antibiotics for preventing recurrent urinary tract infection in non-pregnant women.
        Cochrane Database Syst Rev. 2004; : CD001209
        • Viswanathan V.K.
        Off-label abuse of antibiotics by bacteria.
        Gut Microbes. 2014; 5: 3-4
        • Regal R.E.
        • Pham C.Q.
        • Bostwick T.R.
        Urinary tract infections in extended care facilities: Preventive management strategies.
        Consult Pharm. 2006; 21: 400-409
        • Khan A.R.
        • Khan S.
        • Zimmerman V.
        • et al.
        Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines.
        Clin Infect Dis. 2010; 51: 1147-1156
        • Castello T.
        • Girona L.
        • Gomez M.R.
        • et al.
        The possible value of ascorbic acid as a prophylactic agent for urinary tract infection.
        Spinal Cord. 1996; 34: 592-593
        • Hetey S.K.
        • Kleinberg M.L.
        • Parker W.D.
        • Johnson E.W.
        Effect of ascorbic acid on urine pH in patients with injured spinal cords.
        Am J Hosp Pharm. 1980; 37: 235-237
        • Barton C.H.
        • Sterling M.L.
        • Thomas R.
        • et al.
        Ineffectiveness of intravenous ascorbic acid as an acidifying agent in man.
        Arch Intern Med. 1981; 141: 211-212
        • Ochoa-Brust G.J.
        • Fernandez A.R.
        • Villanueva-Ruiz G.J.
        • et al.
        Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy.
        Acta Obstet Gynecol Scand. 2007; 86: 783-787
        • McDonald D.F.
        • Murphy G.P.
        Bacteriostatic and acidifying effects of methionine, hydrolyzed casein and ascorbic acid on the urine.
        N Engl J Med. 1959; 261: 803-805
        • Bergman J.
        • Schjott J.
        • Blix H.S.
        Prevention of urinary tract infections in nursing homes: Lack of evidence-based prescription?.
        BMC Geriatr. 2011; 11: 69
        • Ferraro P.M.
        • Curhan G.C.
        • Gambaro G.
        • Taylor E.N.
        Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones.
        Am J Kidney Dis. 2016; 67: 400-407
        • Traxer O.
        • Huet B.
        • Poindexter J.
        • et al.
        Effect of ascorbic acid consumption on urinary stone risk factors.
        J Urol. 2003; 170: 397-401
        • Robitaille L.
        • Mamer O.A.
        • Miller Jr., W.H.
        • et al.
        Oxalic acid excretion after intravenous ascorbic acid administration.
        Metabolism. 2009; 58: 263-269
      1. Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids.
        National Academies Press (US), Washington (DC)2000
        • Howell A.B.
        • Botto H.
        • Combescure C.
        • et al.
        Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: A multicentric randomized double blind study.
        BMC Infect Dis. 2010; 10: 94
        • Blumberg J.B.
        • Basu A.
        • Krueger C.G.
        • et al.
        Impact of cranberries on gut microbiota and cardiometabolic health: Proceedings of the Cranberry Health Research Conference 2015.
        Ad Nutr. 2016; 7: 759s-770s
        • Feliciano R.P.
        • Krueger C.G.
        • Reed J.D.
        Methods to determine effects of cranberry proanthocyanidins on extraintestinal infections: Relevance for urinary tract health.
        Mol Nutr Food Res. 2015; 59: 1292-1306
        • Feliciano R.P.
        • Meudt J.J.
        • Shanmuganayagam D.
        • et al.
        Ratio of “A-type” to “B-type” proanthocyanidin interflavan bonds affects extra-intestinal pathogenic Escherichia coli invasion of gut epithelial cells.
        J Agric Food Chem. 2014; 62: 3919-3925
        • Sun J.
        • Marais J.P.
        • Khoo C.
        • et al.
        Cranberry (Vaccinium macrocarpon) oligosaccharides decrease biofilm formation by uropathogenic Escherichia coli.
        J Funct Foods. 2015; 17: 235-242
        • Huang Y.
        • Nikolic D.
        • Pendland S.
        • et al.
        Effects of cranberry extracts and ursolic acid derivatives on P-fimbriated Escherichia coli, COX-2 activity, pro-inflammatory cytokine release and the NF-kappabeta transcriptional response in vitro.
        Pharm Biol. 2009; 47: 18-25
        • Avorn J.
        • Monane M.
        • Gurwitz J.H.
        • et al.
        Reduction of bacteriuria and pyuria after ingestion of cranberry juice.
        JAMA. 1994; 271: 751-754
        • Haverkorn M.J.
        • Mandigers J.
        Reduction of bacteriuria and pyuria using cranberry juice.
        JAMA. 1994; 272: 590
        • McMurdo M.E.
        • Bissett L.Y.
        • Price R.J.
        • et al.
        Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial.
        Age Ageing. 2005; 34: 256-261
        • McMurdo M.E.
        • Argo I.
        • Phillips G.
        • et al.
        Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women.
        J Antimicrob Chemother. 2009; 63: 389-395
        • Caljouw M.A.
        • van den Hout W.B.
        • Putter H.
        • et al.
        Effectiveness of cranberry capsules to prevent urinary tract infections in vulnerable older persons: A double-blind randomized placebo-controlled trial in long-term care facilities.
        J Am Geriatr Soc. 2014; 62: 103-110
        • Juthani-Mehta M.
        • Van Ness P.H.
        • Bianco L.
        • et al.
        Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: A randomized clinical trial.
        JAMA. 2016; 316: 1879-1887
        • Juthani-Mehta M.
        • Perley L.
        • Chen S.
        • et al.
        Feasibility of cranberry capsule administration and clean-catch urine collection in long-term care residents.
        J Am Geriatr Soc. 2010; 58: 2028-2030
        • Bianco L.
        • Perrelli E.
        • Towle V.
        • et al.
        Pilot randomized controlled dosing study of cranberry capsules for reduction of bacteriuria plus pyuria in female nursing home residents.
        J Am Geriatr Soc. 2012; 60: 1180-1181
        • Ledda A.
        • Belcaro G.
        • Dugall M.
        • et al.
        Supplementation with high titer cranberry extract (Anthocran(R)) for the prevention of recurrent urinary tract infections in elderly men suffering from moderate prostatic hyperplasia: A pilot study.
        Eur Rev Med Pharmacol Sci. 2016; 20: 5205-5209
        • Hooton T.M.
        • Vecchio M.
        • Iroz A.
        • et al.
        Prevention of recurrent acute uncomplicated cystitis by increasing daily water in premenopausal women: A prospective, randomized, controlled study.
        Open Forum Infect Dis. 2017; 4 (S736–S736)
        • Rowe T.A.
        • Juthani-Mehta M.
        Urinary tract infection in older adults.
        Aging Health. 2013; 9
        • Wang C.H.
        • Fang C.C.
        • Chen N.C.
        • et al.
        Cranberry-containing products for prevention of urinary tract infections in susceptible populations: A systematic review and meta-analysis of randomized controlled trials.
        Arch Intern Med. 2012; 172: 988-996
        • Terris M.K.
        • Issa M.M.
        • Tacker J.R.
        Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis.
        Urology. 2001; 57: 26-29
        • Li Z.
        • Seeram N.P.
        • Carpenter C.L.
        • et al.
        Cranberry does not affect prothrombin time in male subjects on warfarin.
        J Am Diet Assoc. 2006; 106: 2057-2061
        • Srinivas N.R.
        Cranberry juice ingestion and clinical drug-drug interaction potentials: Review of case studies and perspectives.
        J Pharm Pharm Sci. 2013; 16: 289-303
        • Ngo N.
        • Brantley S.J.
        • Carrizosa D.R.
        • et al.
        The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation.
        J Exp Pharmacol. 2010; 2010: 83-91
        • Zunino P.
        • Sosa V.
        • Schlapp G.
        • et al.
        Mannose-resistant Proteus-like and P. mirabilis fimbriae have specific and additive roles in P. mirabilis urinary tract infections.
        FEMS Immunol Med Microbiol. 2007; 51: 125-133
        • Kranjcec B.
        • Papes D.
        • Altarac S.
        d-Mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial.
        World J Urol. 2014; 32: 79-84
        • Davis J.A.
        • Freeze H.H.
        Studies of mannose metabolism and effects of long-term mannose ingestion in the mouse.
        Biochim Biophys Acta. 2001; 1528: 116-126
        • Raz R.
        Postmenopausal women with recurrent UTI.
        Int J Antimicrob Agents. 2001; 17: 269-271
        • Raz R.
        • Stamm W.E.
        A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
        N Engl J Med. 1993; 329: 753-756
        • Eriksen B.
        A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women.
        Am J Obstet Gynecol. 1999; 180: 1072-1079
        • Raz R.
        • Colodner R.
        • Rohana Y.
        • et al.
        Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women.
        Clin Infect Dis. 2003; 36: 1362-1368
        • ACOG Committee opinion no
        556: Postmenopausal estrogen therapy: Route of administration and risk of venous thromboembolism.
        Obstet Gynecol. 2013; 121: 887-890
        • Henriksson L.
        • Stjernquist M.
        • Boquist L.
        • et al.
        A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging.
        Am J Obstet Gynecol. 1996; 174: 85-92
        • Farrell R.
        ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer.
        Obstet Gynecol. 2016; 127: e93-e96
        • Wills S.
        • Ravipati A.
        • Venuturumilli P.
        • et al.
        Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.
        J Oncol Pract. 2012; 8: 144-148
        • Reid G.
        Probiotic agents to protect the urogenital tract against infection.
        Am J Clin Nutr. 2001; 73: 437s-443s
        • Kwok L.
        • Stapleton A.E.
        • Stamm W.E.
        • et al.
        Adherence of Lactobacillus crispatus to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection.
        J Urol. 2006; 176 (discussion 2054): 2050-2054
        • Czaja C.A.
        • Stapleton A.E.
        • Yarova-Yarovaya Y.
        • Stamm W.E.
        Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women.
        Infect Dis Obstet Gynecol. 2007; 2007: 35387
        • Stapleton A.E.
        • Au-Yeung M.
        • Hooton T.M.
        • et al.
        Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.
        Clin Infect Dis. 2011; 52: 1212-1217
        • Beerepoot M.A.
        • ter Riet G.
        • Nys S.
        • et al.
        Lactobacilli vs antibiotics to prevent urinary tract infections: A randomized, double-blind, noninferiority trial in postmenopausal women.
        Arch Intern Med. 2012; 172: 704-712
        • Piaggio G.
        • Elbourne D.R.
        • Pocock S.J.
        • et al.
        Reporting of noninferiority and equivalence randomized trials: Extension of the CONSORT 2010 statement.
        JAMA. 2012; 308: 2594-2604
        • Boyle R.J.
        • Robins-Browne R.M.
        • Tang M.L.
        Probiotic use in clinical practice: What are the risks?.
        Am J Clin Nutr. 2006; 83 (quiz 1446–1257): 1256-1264
        • Mehta A.
        • Rangarajan S.
        • Borate U.
        A cautionary tale for probiotic use in hematopoietic SCT patients—Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT.
        Bone Marrow Transplant. 2013; 48: 461-462
        • Redman M.G.
        • Ward E.J.
        • Phillips R.S.
        The efficacy and safety of probiotics in people with cancer: A systematic review.
        Ann Oncol. 2014; 25: 1919-1929
        • Ledoux D.
        • Labombardi V.J.
        • Karter D.
        Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease.
        Int J STD AIDS. 2006; 17: 280-282
        • Kochan P.
        • Chmielarczyk A.
        • Szymaniak L.
        • et al.
        Lactobacillus rhamnosus administration causes sepsis in a cardiosurgical patient—Is the time right to revise probiotic safety guidelines?.
        Clin Microbiol Infect. 2011; 17: 1589-1592
        • Methenamine hippurate (Hiprex)
        Med Lett Drugs Ther. 1968; 10: 58-60
        • Brumfitt W.
        • Cooper J.
        • Hamilton-Miller J.M.
        Prevention of recurrent urinary infections in women: A comparative trial between nitrofurantoin and methenamine hippurate.
        J Urol. 1981; 126: 71-74
        • Norberg B.
        • Norberg A.
        • Parkhede U.
        • Gippert H.
        Effect of short-term high-dose treatment with methenamine hippurate on urinary infection in geriatric patients with an indwelling catheter, IV: Clinical evaluation.
        Eur J Clin Pharmacol. 1979; 15: 357-361
      2. Product Information: HIPREX® oral tables, methenamine hippurate oral tablets. Merrel Pharmaceuticals Inc, Bridgewood, NJ2004
        • Saint S.
        • Greene M.T.
        • Krein S.L.
        • et al.
        A program to prevent catheter-associated urinary tract infection in acute care.
        N Engl J Med. 2016; 374: 2111-2119
        • Mody L.
        • Greene M.T.
        • Meddings J.
        • et al.
        A national implementation project to prevent catheter-associated urinary tract infection in nursing home residents.
        JAMA Intern Med. 2017; 177: 1154-1162